BioTech Health XApril 20, 2022 Biotech NewsEF Hutton Initiates Coverage of Cel-Sci (CVM) with $17 Price Target Ahead of Rumored News 5 minute read Tim Moore, CFA an Analyst at EF Hutton has recently published a report citing the opportunities for growth… 0 Shares 0 0 0 0 0 0 0
Jak ThomsonSeptember 7, 2021 BioTech CEO InterviewsExclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future 10 minute read About Cel-Sci Corporation Cel-Sci Corporation is a publicly traded biotechnology business which develops, manufactures, and markets treatments focused… 0 Shares 0 0 0 0 0 0 0
BioTech Health XJuly 27, 2021 Biotech NewsRecent Report Highlights Success in FDA Subgroup Approval & Treatment Arm Data 9 minute read A recent report published by the American Association for Cancer Research titled Subgroup Analyses in Oncology Trials: Regulatory… 0 Shares 0 0 0 0 0 0 0